Li W - Search Results

1

Efficacy and safety of levetiracetam versus (fos)phenytoin for second-line treatment of epilepticus: a meta-analysis of latest randomized controlled trials.

Feng Y, Chen Y, Jia Y, Wang Z, Wang X, Jiang L, Ai C, Li W, Liu Y. Feng Y, et al. Among authors: li w. Seizure. 2021 Oct;91:339-345. doi: 10.1016/j.seizure.2021.07.012. Epub 2021 Jul 13. Seizure. 2021. PMID: 34284302 Free article. Review.

2

Risk prediction of drug-drug interaction potential of phenytoin and miconazole topical formulations.

Li W, Wang Z, Wang X, Cao X, Bi C, Jiang L, Cui S, Liu Y. Li W, et al. Chem Biol Interact. 2021 Jul 1;343:109498. doi: 10.1016/j.cbi.2021.109498. Epub 2021 May 4. Chem Biol Interact. 2021. PMID: 33961833

3

Potential herb-drug interaction risk of thymoquinone and phenytoin.

Wang Z, Wang X, Wang Z, Lv X, Yin H, Li W, Li W, Jiang L, Liu Y. Wang Z, et al. Among authors: li w. Chem Biol Interact. 2022 Feb 1;353:109801. doi: 10.1016/j.cbi.2022.109801. Epub 2022 Jan 6. Chem Biol Interact. 2022. PMID: 34998822

4

The association between CYP2C9/2C19 polymorphisms and phenytoin maintenance doses in Asian epileptic patients: A systematic review and meta-analysis .

Liao K, Liu Y, Ai CZ, Yu X, Li W. Liao K, et al. Among authors: li w. Int J Clin Pharmacol Ther. 2018 Jul;56(7):337-346. doi: 10.5414/CP203083. Int J Clin Pharmacol Ther. 2018. PMID: 29628024 Review.

5

Potential food-drug interaction risk of thymoquinone with warfarin.

Wang Z, Wang Z, Wang X, Lv X, Yin H, Jiang L, Xia Y, Li W, Li W, Liu Y. Wang Z, et al. Among authors: li w. Chem Biol Interact. 2022 Sep 25;365:110070. doi: 10.1016/j.cbi.2022.110070. Epub 2022 Jul 31. Chem Biol Interact. 2022. PMID: 35921950

6

Computational prediction for the metabolism of human UDP-glucuronosyltransferase 1A1 substrates.

Luo YB, Hou YY, Wang Z, Hu XM, Li W, Li Y, Liu Y, Li TJ, Ai CZ. Luo YB, et al. Among authors: li y, li w, li tj. Comput Biol Med. 2022 Oct;149:105959. doi: 10.1016/j.compbiomed.2022.105959. Epub 2022 Aug 19. Comput Biol Med. 2022. PMID: 36063691

7

Inhibition of SN-38 glucuronidation by gefitinib and its metabolite.

Li W, Xing Y, Liu Y. Li W, et al. Cancer Chemother Pharmacol. 2015 Jun;75(6):1253-60. doi: 10.1007/s00280-015-2753-4. Epub 2015 Apr 28. Cancer Chemother Pharmacol. 2015. PMID: 25917289

8

Association between ABCB1 C3435T polymorphism and antiepileptic drug resistance in epilepsy: An updated meta-analysis based on 62 studies.

Chen YY, Feng YY, Chen YN, Cao YM, Ai CZ, Bi CL, Liu Y, Li W. Chen YY, et al. Among authors: li w. Int J Clin Pharmacol Ther. 2022 Mar;60(3):146-158. doi: 10.5414/CP204045. Int J Clin Pharmacol Ther. 2022. PMID: 34846299

9

Computational explanation for bioactivation mechanism of targeted anticancer agents mediated by cytochrome P450s: A case of Erlotinib.

Ai CZ, Liu Y, Li W, Chen DM, Zhu XX, Yan YW, Chen DC, Jiang YZ. Ai CZ, et al. Among authors: li w. PLoS One. 2017 Jun 19;12(6):e0179333. doi: 10.1371/journal.pone.0179333. eCollection 2017. PLoS One. 2017. PMID: 28628631 Free PMC article.

10

Anti-androgen-independent prostate cancer effects of ginsenoside metabolites in vitro: mechanism and possible structure-activity relationship investigation.

Li W, Liu Y, Zhang JW, Ai CZ, Xiang N, Liu HX, Yang L. Li W, et al. Arch Pharm Res. 2009 Jan;32(1):49-57. doi: 10.1007/s12272-009-1117-1. Epub 2009 Jan 29. Arch Pharm Res. 2009. PMID: 19183876

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

82,500 results

Search Page

Filters